Form 4: MannKind Corp Executive Dominic Marasco Reports Stock Transactions

Dominic Marasco, President of the Endocrine Business Unit at MannKind Corp, reports acquisition of shares through a restricted stock unit award and a market price stock purchase plan.

Summary

• Dominic Marasco, the President of the Endocrine Business Unit at MannKind Corp, filed a Form 4 detailing changes in beneficial ownership.
• On May 14, 2025, Marasco acquired 59,500 shares of common stock through a Restricted Stock Unit (RSU) award, which vests 25% annually starting July 15, 2026.
• Also on May 14, 2025, Marasco acquired 21,929 shares through the Issuer's Market Price Stock Purchase Plan at a price of $4.56 per share.
• Marasco also acquired 72,500 performance-based restricted stock units that will vest on July 15, 2028, with the number of shares delivered depending on MannKind's total shareholder return (TSR) relative to the Russell 3000 Pharmaceutical & Biotechnology Index.

Sentiment

Score: 6

Explanation: Neutral sentiment as it's a standard reporting of insider transactions. The acquisitions suggest confidence, but it's routine.

Positives

• The acquisition of shares through the Market Price Stock Purchase Plan demonstrates Marasco's investment in the company's stock.
• The vesting schedule of the RSUs incentivizes long-term performance and commitment from Marasco.

Risks

• The value of the performance-based restricted stock units is contingent on MannKind's TSR performance, which may not meet the required percentile for full vesting.

Future Outlook

The vesting of the RSUs and performance-based RSUs are tied to future dates and performance metrics, indicating a long-term incentive structure.

Industry Context

Form 4 filings are standard practice for company insiders to report transactions in their company's stock, providing transparency to investors.

Comparison to Industry Standards

• Stock purchase plans and RSU grants are common compensation methods in the pharmaceutical and biotechnology industries.
• Performance-based vesting criteria, such as TSR relative to an index, are also frequently used to align executive compensation with shareholder value.
• Companies like Amgen, Gilead Sciences, and Biogen often utilize similar compensation structures for their executives.

Stakeholder Impact

• The insider transactions provide transparency to shareholders regarding management's stake in the company.
• The vesting schedule of the RSUs aligns management's interests with long-term shareholder value.

Key Dates

Keywords

Form 4, MannKind Corp, MNKD, Dominic Marasco, Restricted Stock Unit, Market Price Stock Purchase Plan, Beneficial Ownership, TSR, Russell 3000 Pharmaceutical & Biotechnology Index